+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy



Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy



Pakistan Journal of Medical Sciences 33(1): 142-145



To compare effectiveness of pan-retinal photocoagulation alone versus panretinal photocoagulation combined with intravitreal bevacizumab on visual acuity and central macular thickness in patients presenting with proliferative diabetic retinopathy. This Randomized controlled trial was carried out at Armed Forces Institute of ophthalmology, Pakistan from Jan 2016 to Aug 2016. Seventy six eyes of 50 patients having proliferative diabetic retinopathy and diabetic macular edema were included in the study. All the patients were subjected to detailed clinical examination that included Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), slit lamp examination of anterior and posterior segments. Optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) were carried out and patients were divided in two groups (GP and GI). Three monthly sessions of Pan retinal photocoagulation (PRP) using Pattern Scan Laser (PASCAL) alone was performed in group GP while PRP along with three monthly intravitreal bevacizumab (IVB) was performed in group GI. BCVA and CMT was recorded 04 weeks after the third PRP session in both the groups. Seventy six eyes of 50 patients (38 in each group) were treated with three sessions of PRP alone and PRP with IVB in Group GP and GI respectively. Mean age of the patient in group GP was 57.47± 6.08 years while that in group GI was 55.69 ±6.58. The magnitude of induced change in BCVA was 0.09 ± 0.15 in GP while 0.22 + 0.04 in GI groups while mean induced change in CMT after treatment was 77.44 ± 92.30 um and 117.50 ± 93.82 um in group GP and GI. Laser PRP combined with IVB has superior visual and anatomical outcome than PRP alone in patients with combined presentation of PDR and DME.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059667759

Download citation: RISBibTeXText

PMID: 28367188

DOI: 10.12669/pjms.331.11497


Related references

Choroidal Thickness Changes in Proliferative Diabetic Retinopathy Treated with Panretinal Photocoagulation Versus Panretinal Photocoagulation with Intravitreal Bevacizumab. Retina 36(10): 1997-2005, 2016

Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy. International Journal of Ophthalmology 9(12): 1772-1778, 2016

Panretinal Photocoagulation Plus Intravitreal Bevacizumab Versus Panretinal Photocoagulation Alone for Proliferative Diabetic Retinopathy. Journal of the College of Physicians and Surgeons--Pakistan 28(12): 923-927, 2018

Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy. Journal of Ayub Medical College Abbottabad 24(3-4): 10-13, 2014

Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmologica 90(7): E573-E574, 2012

Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 29(4): 516-522, 2009

Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean Journal of Ophthalmology 23(4): 266-272, 2009

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmologica 86(4): 385-389, 2008

The Effect of Panretinal Photocoagulation (PRP) versus Intravitreal Bevacizumab (IVB) Plus PRP on Peripapillary Retinal Nerve Fiber Layer (RNFL) Thickness Analyzed by Optical Coherence Tomography in Patients with Proliferative Diabetic Retinopathy. Journal of Ophthalmic and Vision Research 14(2): 157-163, 2019

Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy. Journal of Ocular Pharmacology and Therapeutics 29(6): 550-555, 2014

Single-dose Intravitreal Bevacizumab after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: an Effective Adjunctive Treatment. Medical Hypothesis Discovery and Innovation Ophthalmology Journal 6(3): 76-81, 2017

Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmologica 89(1): 76-81, 2011

Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 29(8): 1134-1140, 2009

Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology 125(5): 691-700, 2018

Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy. Seminars in Ophthalmology 16(1): 12-18, 2001